Chang Shuang, Ding Zhuang, Dunn John R, Lee Lucy F, Heidari Mohammad, Song Jiuzhou, Ernst Catherine W, Zhang Huanmin
United States Department of Agriculture, Agriculture Research Service, Avian Disease and Oncology Laboratory, 3606 E. Mount Hope Road, East Lansing, MI 48823, USA.
Avian Dis. 2011 Sep;55(3):384-90. doi: 10.1637/9524-091310-Reg.1.
Marek's disease (MD) is a lymphoproliferative disease of domestic chickens caused by a highly infectious, oncogenic alpha-herpesvirus known as Marek's disease virus (MDV). MD is presently controlled by vaccination. Current MD vaccines include attenuated serotype 1 strains (e.g., CVI988/Rispens), avirulent serotype 2 (SB-1), and serotype 3 (HVT) MDV strains. In addition, recombinant MDV strains have been developed as potential new and more efficient vaccines to sustain the success of MD control in poultry. One of the candidate recombinant MDV strains, named rMd5deltaMeq, was derived from Md5, a very virulent strain of MDV lacking the MDV oncogene Meq. Our earlier reports suggest that rMd5deltaMeq provided protection equally well or better than commonly used MD vaccines in experimental and commercial lines of chickens challenged with very virulent plus (vv+) strains of MDV. In this study, maternal antibody-positive (trial 1) and negative (trial 2) chickens from a series of relatively MD resistant lines were either vaccinated with the rMd5deltaMeq or CVI988/Rispens followed by infection of a vv+ strain of MDV, 648A, passage 10. This report presents experimental evidence that the rMd5deltaMeq protected significantly better than the CVI988/Rispens (P < 0.01) in the relatively resistant experimental lines of chickens challenged with the vv+ strain of MDV. Together with early reports, the rMd5deltaMeq appeared to provide better protection, comparing with the most efficacious commercially available vaccine, CVI988/Rispens, for control of MD in lines of chickens regardless of their genetic background.
马立克氏病（MD）是由一种高度传染性的致癌α疱疹病毒——马立克氏病病毒（MDV）引起的家鸡淋巴增生性疾病。目前，MD通过疫苗接种来控制。当前的MD疫苗包括减毒1型毒株（如CVI988/里氏株）、无毒2型（SB - 1）和3型（HVT）MDV毒株。此外，重组MDV毒株已被开发为潜在的新型高效疫苗，以维持家禽MD防控的成效。其中一种候选重组MDV毒株，名为rMd5deltaMeq，源自Md5，这是一种非常强毒的MDV毒株，缺失MDV癌基因Meq。我们早期的报告表明，在受到超强毒加（vv +）MDV毒株攻击的实验鸡群和商业鸡群中，rMd5deltaMeq提供的保护与常用的MD疫苗相当或更好。在本研究中，来自一系列相对抗MD品系的母源抗体阳性（试验1）和阴性（试验2）鸡，分别接种rMd5deltaMeq或CVI988/里氏株，随后感染vv + MDV毒株648A，第10代。本报告提供了实验证据，即在受到vv + MDV毒株攻击的相对抗性实验鸡群中，rMd5deltaMeq提供的保护显著优于CVI988/里氏株（P < 0.01）。与早期报告一起，与最有效的市售疫苗CVI988/里氏株相比，rMd5deltaMeq似乎能为不同遗传背景的鸡群提供更好的MD防控保护。
